ValueScreener

ValueScreener company report

PharmaCyte Biotech, Inc. (PMCB)

NASDAQ / Healthcare / Biotechnology

Share price

0.36 USD Market dataClose of Oct 15, 2026

Market capitalisation

3.8M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2026, filed Jul 29, 2026
Ratios computed
Oct 15, 2026
Filed years
15, FY2012 to FY2026
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-58.3% Computed

From the FY2026 filing

Read quality

Valuation

Price to book

0.09x Computed

FY2026 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

n/a Computed

FY2026 accounts, priced at the latest close

Why n/a

We do not hold this figure for this company, so there is nothing to show.

Read cash generation

Revenue and net income, as filed

FY2017 Revenue: 0.00 USDFY2017 Net income: -4.4M USDFY2018 Revenue: 0.00 USDFY2018 Net income: -6.8M USDFY2019 Revenue: 0.00 USDFY2019 Net income: -4.1M USDFY2020 Revenue: 0.00 USDFY2020 Net income: -3.8M USDFY2021 Revenue: 0.00 USDFY2021 Net income: -3.6M USDFY2022 Revenue: 0.00 USDFY2022 Net income: -4.2M USDFY2023 Revenue: 0.00 USDFY2023 Net income: -4.3M USDFY2024 Revenue: 0.00 USDFY2024 Net income: 333.8K USDFY2025 Revenue: 0.00 USDFY2025 Net income: 30.7M USDFY2026 Revenue: 0.00 USDFY2026 Net income: -19.4M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
2 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -58.3% in FY2026, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Biotechnology industry (494 companies), -58.3% sits at the 52nd percentile; the middle half of that group runs from -146.9% to -28.9%.

Is it safe

Current ratio was 45.28 in FY2026, in the band labelled "At or above Graham's requirement" (2.00 and above), on lines anchored on Graham's defensive-investor criteria, suggesting short-term assets well above short-term obligations.

Today, against the Biotechnology industry (556 companies), 45.28 sits at the 100th percentile; the middle half of that group runs from 2.39 to 9.18.

Year by year against peers
Whether PharmaCyte Biotech, Inc.'s return on equity stayed above the median of the Biotechnology industry, year by year. (FY2022 to FY2026, 5 fiscal years of PharmaCyte Biotech, Inc. with a comparable figure)
The direction
Which way PharmaCyte Biotech, Inc.'s return on equity has moved, and how steadily. (FY2017 to FY2026, 10 filed years of PharmaCyte Biotech, Inc.)
What could explain it
What in PharmaCyte Biotech, Inc.'s filed statements could explain the movements. (2 readings drawn from the statement lines PharmaCyte Biotech, Inc. filed)
What to check next
What to check next on PharmaCyte Biotech, Inc., and where in its filings. (1 question for PharmaCyte Biotech, Inc.)
In one paragraph
One paragraph on PharmaCyte Biotech, Inc.'s returns, cash, balance sheet and price. (3 of sixteen figures read for PharmaCyte Biotech, Inc.)

These are PMCB’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research PMCBPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2026 annual report: 10-K, filed Jul 29, 2026, accession 0001683168-26-005836.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

PharmaCyte Biotech, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Return on equity-58.3% ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Return on capital employed, pre-tax-14.9% ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Return on assets-41.5% ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Gross margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Operating margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Net margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

PharmaCyte Biotech, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.

n/a ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Current ratio45.28 ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Quick ratio45.28 ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Altman Z-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Net debt
Why n/a

The FY2026 balance sheet carries no net debt we could read.

n/a ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Total assets 46.8MTotal liabilities 11.8MShareholders' equity 33.3MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What PharmaCyte Biotech, Inc owned and owed at the end of fiscal 2026, from the balance sheet it filed (10-K, filed Jul 29, 2026, 0001683168-26-005836).

PharmaCyte Biotech, Inc: balance sheet position
Total assets46.8M FiledFY2026 10-K, filed Jul 29, 2026
Total liabilities11.8M FiledFY2026 10-K, filed Jul 29, 2026
Shareholders' equity33.3M FiledFY2026 10-K, filed Jul 29, 2026
Cash18.9M FiledFY2026 10-K, filed Jul 29, 2026
Total debtn/a FiledFY2026 10-K, filed Jul 29, 2026
Net debtn/a
Current ratio45.28
Debt to equityn/a
  • Debt to equity: FY2026: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Interest cover: FY2026: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

PharmaCyte Biotech, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
P/E on trailing twelve months13.75x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book0.09x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Price to sales
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Enterprise value to EBITDA
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Diluted earnings per share-2.77 USD FiledFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836

We publish no fair value or price target of our own. Value PMCB on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for PharmaCyte Biotech, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

PharmaCyte Biotech, Inc: valuation
Share price0.36 USD
Market capitalisation3.8M USD
Enterprise value to EBITDAn/a
Graham numbern/m
Diluted earnings per share, FY2026-2.77 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Oct 3, 2016: low 0.26x, median 3.00x, high 20.33x, latest 13.75x. 377 trading days with a meaningful ratio, 2,146 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like PharmaCyte Biotech, Inc

  1. Enlivex Therapeutics Ltd. (ENLV)Market cap 3.8M USD
  2. Pulmatrix, Inc. (PULM)Market cap 5.2M USD
  3. XORTX Therapeutics Inc. (XRTX)Market cap 2.6M USD
  4. Malachite Innovations, Inc. (VBIO)Market cap 2.4M USD
  5. Kairos Pharma, Ltd. (KAPA)Market cap 2.3M USD

Same industry (Biotechnology) and size band (Nano, under 50M), nearest in market value and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

Computed

PharmaCyte Biotech, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Free cash flow
Why n/a

The FY2026 filing carries no free cash flow we could read.

n/a ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Free cash flow margin
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Dividend yield
Why n/a

The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.

n/a ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
FY2017 Net income: -4.4M USDFY2018 Net income: -6.8M USDFY2019 Net income: -4.1M USDFY2020 Net income: -3.8M USDFY2021 Net income: -3.6M USDFY2022 Net income: -4.2M USDFY2023 Net income: -4.3M USDFY2024 Net income: 333.8K USDFY2025 Net income: 30.7M USDFY2026 Net income: -19.4M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

PharmaCyte Biotech, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.09xFY2026Oct 15, 2026
n/aFY2026Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
n/aFY2026Oct 15, 2026
n/a The filed cash flow statement reports neither free cash flow nor the operating cash flow and capital spending it is built from.
n/aFY2026Jul 29, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
n/aFY2026Oct 15, 2026
n/a The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.
n/aFY2026Jul 29, 2026
n/a The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
45.28FY2026Jul 29, 2026
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2026Jul 29, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/mFY2026Jul 29, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

The figures are computed from the accounts for fiscal 2026, the newest full year on file. 15 filed fiscal years on record, FY2012 to FY2026, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2017 to FY2026, read from the annual reports PharmaCyte Biotech, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

PharmaCyte Biotech, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY20260.00-6.9M-19.4M-2.77n/an/m-58.3%10-K, Jul 29, 20260001683168-26-005836
FY20250.00-4.4M30.7M3.19n/an/m59.1%10-K, Aug 11, 20250001683168-25-005821
FY20240.00-8.5M333.8K-1.80n/an/m1.2%10-K, Aug 13, 20240001683168-24-005575
FY20230.00-6.5M-4.3M-0.22n/an/m-5.9%10-K, Jul 31, 20230001683168-23-005175
FY20220.00-4.4M-4.2M-0.27n/an/m-4.7%10-K, Jul 28, 20220001683168-22-005189
FY20210.00-3.6M-3.6M-2.45n/an/m-53.2%10-K, Aug 10, 20210001683168-21-003377
FY20200.00-3.8M-3.8M-4.23n/an/m-75.2%10-K, Aug 13, 20200001683168-20-002680
FY20190.00-4.1M-4.1M0.00n/an/m-80.7%10-K, Aug 13, 20190001683168-19-002559
FY20180.00-7.0M-6.8M-15.50n/an/m-118.4%10-K, Jul 20, 20180001683168-18-001994
FY20170.00-4.4M-4.4M-15.50n/an/m-55.0%10-K, Jul 27, 20170001683168-17-001881
  • Revenue: Revenue was not positive in both 2017 and 2026, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings: Earnings was not positive in both 2017 and 2026, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2017 and 2026, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Fewer than two filed years carry free cash flow.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

PharmaCyte Biotech, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Piotroski F-score
Why n/m

This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.

n/m ComputedFY2026 10-K, filed Jul 29, 2026, 0001683168-26-005836
Named tests met2 of 30 Computed
Beta0.81 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 2 met, 9 not met, 19 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
Two thirds of NCAV (Benjamin Graham); Cheapest quarter on P/B (David Dreman)
Does not
Defensive investor (Benjamin Graham); Large cap, low P/E; High returns and growth; Dividends and buybacks; Low beta, profitable; High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy)
Not measured
Deep value; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; ROIC at or above WACC; Near the 52-week low; Z-score and coverage (Edward Altman); P/E times P/B (Benjamin Graham); Book or below, low debt (Walter Schloss); Cash-covered dividend; Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(23)
  • Debt to Equity: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Piotroski F-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • Return on Invested Capital: The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read.
  • Altman Z-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Beneish M-Score: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Rev Growth 5Y: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Gross Margin: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Asset Turnover: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • EV/EBITDA: We do not hold this figure for this company, so there is nothing to show.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Free Cash Flow Yield: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Capex To Ocf: We do not hold this figure for this company, so there is nothing to show.
  • P/S Ratio: This company reported no revenue for the period, so every ratio measured against revenue is undefined. It is not a zero margin, it is the absence of a denominator. Cash runway is the measure that applies.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 23 figures could not be read on this company, among them Debt to Equity, Piotroski F-Score, P/E Ratio. Each blank in the table above names the rest, with its reason. 19 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy